Severe Acute Respiratory Syndrome Coronavirus 2
Respiratory·MeSH: COVID-19
Prevalence
0.1 / 100K
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| paxlovid | PFIZER INC (PFE) |
Phase 3(1)
| Drug | Company |
|---|---|
| nvx-cov2705 vaccine | NOVAVAX INC (NVAX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Severe Acute Respiratory Syndrome Coronavirus 2?
BioSniper tracks 2 drugs in development for Severe Acute Respiratory Syndrome Coronavirus 2 across 2 companies.
How many clinical trials target Severe Acute Respiratory Syndrome Coronavirus 2?
There are 2 clinical trials targeting Severe Acute Respiratory Syndrome Coronavirus 2 tracked by BioSniper.
What is the prevalence of Severe Acute Respiratory Syndrome Coronavirus 2?
The estimated prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 is approximately 0.1 per 100,000 population.
Deep-dive into Severe Acute Respiratory Syndrome Coronavirus 2
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis